Diadem and the University of Texas Medical Branch report new evidence on Alzheimer’s biomarker at CTAD 2026 by minnac | Nov 18, 2026 | Uncategorized
Diadem awarded US patent for AlzoSure® Alzheimer’s disease prediction technology by minnac | Oct 19, 2026 | Uncategorized
Diadem Unveils Novel Findings on Early Alzheimer’s Disease Detection Using p53-Specific Antibody at CTAD 2024 by minnac | Nov 1, 2024 | Uncategorized
Diadem Appoints Michael Rasche as Chief Executive Officer by clairenicholson078 | Jul 10, 2024 | Uncategorized
Diadem SpA Announces Exclusive U.S. Licensing Agreement with Quest Diagnostics for Its AlzoSure® Predict Alzheimer’s Disease Prognostic Technology by clairenicholson078 | Oct 25, 2023 | Uncategorized